HEALEY ALS Platform Trial – Master Protocol

Overview

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

Full Title of Study: “HEALEY ALS Platform Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2025

Detailed Description

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This trial is designed as a perpetual platform trial. This means that there is a single Master Protocol dictating the conduct of the trial. In this trial, multiple investigational products for ALS will be tested simultaneously or sequentially. Each investigational product will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active investigational product and matching placebo will be tested in each regimen. The additional details that govern the testing of each investigational product will be summarized in separate regimen-specific appendices (RSAs). Each regimen will have a separate ClinicalTrials.gov posting, which will include specific information about the regimen. All regimen-specific outcome measures will be detailed in each regimen posting. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized in a 3:1 ratio to either study drug or placebo. The following regimens are active in the trial: Regimen A – Zilucoplan Regimen B – Verdiperstat Regimen C – CNM-Au8 Regimen D – Priodopidine Regimen E – SLS-005 Trehalose Regimen F – ABBV-CLS-7262 Regimen G – DNL343 New regimens will be continuously added as new investigational products become available. The HEALEY ALS Platform Trial will enroll additional participants as each new regimen is available.

Interventions

  • Drug: Zilucoplan
    • Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight
  • Drug: Verdiperstat
    • Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily
  • Drug: CNM-Au8
    • Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily
  • Drug: Pridopidine
    • Drug: Pridopidine Administration: Oral Dose: 45mg twice daily
  • Drug: SLS-005 Trehalose
    • Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly
  • Drug: ABBV-CLS-7262
    • Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2
  • Drug: DNL343
    • Drug: DNL343 Administration: Oral Dose: Once per day

Arms, Groups and Cohorts

  • Experimental: Regimen A – Zilucoplan
    • Participants are randomized to receive either active zilucoplan or matching placebo.
  • Experimental: Regimen B – Verdiperstat
    • Participants are randomized to receive either active verdiperstat or matching placebo.
  • Experimental: Regimen C – CNM-Au8
    • Participants are randomized to receive either active CNM-Au8 or matching placebo.
  • Experimental: Regimen D – Pridopidine
    • Participants are randomized to receive either active Pridopidine or matching placebo.
  • Experimental: Regimen E – SLS-005 Trehalose
    • Participants are randomized to receive either active SLS-005 Trehalose or matching placebo.
  • Experimental: Regimen F- ABBV-CLS-7262
    • Participants are randomized to receive either active ABBV-CLS-7262 or matching placebo.
  • Experimental: Regimen G – DNL343
    • Participants are randomized to receive either active DNL343 or matching placebo.

Clinical Trial Outcome Measures

Primary Measures

  • Disease Progression
    • Time Frame: 24 Weeks
    • Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

Secondary Measures

  • Respiratory Function
    • Time Frame: 24 Weeks
    • Change in respiratory function over time as measured by Slow Vital Capacity (SVC).
  • Muscle Strength
    • Time Frame: 24 Weeks
    • Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).
  • Survival
    • Time Frame: 24 Weeks
    • Comparison of rate of occurrence between groups.

Participating in This Clinical Trial

Inclusion Criteria

1. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria. 2. Age 18 years or older. 3. Capable of providing informed consent and complying with study procedures, in the SI's opinion. 4. Time since onset of weakness due to ALS ≤ 36 months at the time of the Master Protocol Screening Visit. 5. Vital Capacity ≥ 50% of predicted capacity at the time of the Master Protocol Screening Visit measured by Slow Vital Capacity (SVC), or, if required due to pandemic-related restrictions, Forced Vital Capacity (FVC) measured in person. 6. Participants must either not take riluzole or be on a stable dose of riluzole for ≥ 30 days prior to the Master Protocol Screening Visit. 7. Participants must either not take edaravone or have completed at least one cycle (typically 14 days) of edaravone prior to the Master Protocol Screening Visit. 8. Participants must have the ability to swallow pills and liquids at the time of the Master Protocol Screening Visit and, in the SI's opinion, have the ability to swallow for the duration of the study. 9. Geographically accessible to the site. 10. Participants must either not take Relyvrio/ Albrioza or have started Relyvrio/ Albrioza ≥ 30 days prior to the Master Protocol Screening Visit. Exclusion Criteria:

1. Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant, according to SI's judgment (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction), or clinically significant laboratory abnormality or EKG changes. Clinically significant abnormal liver or kidney function is exclusionary. The following values [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) or estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73m2] are exclusionary regardless of clinical symptoms. 2. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed consent, in the SI's opinion. 3. Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. 4. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Master Protocol Screening Visit. 5. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational). 6. If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception, for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment. 7. If male of reproductive capacity, unwilling to use effective contraception for the duration of the trial and for 3 months, or as specified in each RSA, after discontinuing study treatment. 8. Anything that would place the participant at increased risk or preclude the participant's full compliance with or completion of the study, in the SI's opinion. 9. If a participant is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Merit E. Cudkowicz, MD
  • Collaborator
    • Massachusetts General Hospital
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Merit E. Cudkowicz, MD, Chief, Neurology Department – Massachusetts General Hospital
  • Overall Official(s)
    • Merit Cudkowicz, MD, Principal Investigator, Massachusetts General Hospital
  • Overall Contact(s)
    • HEALEY Center for ALS at Massachusetts General Hospital, 833-425-8257 (HALT ALS), healeyalsplatform@mgh.harvard.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.